{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-043601","form_type":"8-K","ticker":"COCH","cik":"0001840877","company_name":"Envoy Medical, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.670947+00:00","generated_at":"2026-06-01T23:32:16.835197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Envoy Medical Q1 revenue $59K, down from $78K; draws $5M from $10M Glen Taylor loan","bullets":["Revenue $59K for Q1 2024 vs $78K in Q1 2023; decrease due to fewer battery replacement requests.","R&D expense increased $0.4M; G&A expense increased $0.7M; sales/marketing down $46K.","Cash and cash equivalents $4.9M as of March 31, 2024.","Entered $10M unsecured loan facility with Glen Taylor; initial draw $5M at 8% interest, five-year term.","All three EFS participants at Mayo completed 12-month follow-up; plan to file IDE for Acclaim CI pivotal trial later in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-043601","json":"https://secwatch.observer/filing/0001213900-24-043601.json","markdown":"https://secwatch.observer/filing/0001213900-24-043601.md","text":"https://secwatch.observer/filing/0001213900-24-043601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840877/000121390024043601/0001213900-24-043601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840877/000121390024043601/ea0206113-8k_envoymed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:32:16.835197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efe8b702f7565c930b18d2d69a68013275bbf6f1","claim":"Envoy Medical, Inc. reported first quarter ended March 31, 2024 results: revenue $59 thousand.","evidence_excerpt":"forward to the prospect of disrupting the hearing industry with new competition and significant innovation.” Financial Results for the Quarter Ended March 31, 2024 Revenue was $59 thousand compared to $78 thousand for the same period in 2023, the decrease is primarily due to a decrease in the number of battery replacement requests received during the three months","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840877/000121390024043601/0001213900-24-043601-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$59 thousand"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}